Ashwagandha (Withania somnifera) is often presented as a natural alternative to prescription anxiety medication, but the two are not clinically interchangeable. Small, mostly short-term trials indicate that certain ashwagandha preparations may reduce perceived stress, some anxiety scores, serum cortisol, or sleep disturbance over several weeks. Prescription medicines, by contrast, have condition-specific indications, standardized dosing, formal safety monitoring, and established roles in moderate, severe, or urgent psychiatric illness.

The most accurate comparison is therefore about clinical role rather than declaring a winner. Human trials have compared ashwagandha with placebo, and one pragmatic trial compared a multicomponent naturopathic program containing ashwagandha with psychotherapy. No direct matched human trial has established that ashwagandha is equivalent to lorazepam, an SSRI, an SNRI, or buspirone. Ashwagandha should not be used to replace these medicines without professional assessment.

Understanding the Comparison

“Anxiolytic” covers medicines with different purposes. Benzodiazepines such as lorazepam can suppress acute anxiety but may cause sedation, physical dependence, and withdrawal reactions. Clinical guidance limits benzodiazepines in generalized anxiety disorder to short-term use during crises. SSRIs are commonly offered when a person with generalized anxiety disorder chooses drug treatment, while other medicines may be selected according to diagnosis, response, contraindications, and adverse effects.

Ashwagandha extracts are multicomponent botanical products rather than a single defined molecule. Their composition varies with plant part, extraction method, solvent, and standardization. Withanolides are prominent constituents, but proposed effects on stress pathways and neurotransmission do not establish that an extract works like a benzodiazepine or antidepressant. A milligram amount from one extract cannot automatically be treated as equivalent to the same milligram amount from another.

Clinical Evidence at a Glance

The following studies are frequently cited in discussions of ashwagandha, stress, anxiety, and sleep. Their designs and populations matter because several did not enroll patients with a formally diagnosed anxiety disorder, and none directly compared ashwagandha with a prescription anxiolytic.

Study Participants Intervention Comparator Verified interpretation
Andrade et al. (2000) 39 adults with ICD-10 anxiety disorders Ethanolic W. somnifera extract for 6 weeks Placebo At week 6, more participants met the study’s response criterion with the extract than with placebo. The sample was small and follow-up was brief.
Cooley et al. (2009) 81 employees with moderate to severe anxiety lasting more than 6 weeks A naturopathic program including root extract 300 mg twice daily, a multivitamin, dietary counseling, and breathing exercises Psychotherapy, matched breathing exercises, and placebo Beck Anxiety Inventory scores fell 56.5% in the naturopathic-care arm and 30.5% in the psychotherapy arm. Because several treatments were bundled together, the result cannot be attributed to ashwagandha alone.
Chandrasekhar et al. (2012) 64 adults with chronic stress Root extract 300 mg twice daily for 60 days Placebo Several stress-rating scores and serum cortisol favored the extract. This was a chronic-stress trial rather than a comparison with an anxiolytic drug.
Lopresti et al. (2019) 60 healthy adults reporting elevated stress Standardized extract 240 mg daily for 60 days Placebo Hamilton Anxiety Rating Scale and morning cortisol changes favored ashwagandha; the between-group DASS-21 difference did not reach conventional statistical significance.
Salve et al. (2019) 60 healthy adults with self-reported stress; 58 completed Root extract 250 mg or 600 mg daily for 8 weeks Placebo Both doses improved some stress and sleep measures, while the clearer Hamilton Anxiety Rating Scale effect occurred with 600 mg daily. Cortisol decreased in both active groups.
Langade et al. (2019) 60 adults with insomnia Root extract 300 mg twice daily for 10 weeks Placebo Sleep-onset latency, sleep efficiency, sleep quality, and an anxiety measure improved. This was primarily an insomnia study, not a drug-comparison trial.

What the Evidence Supports

A 2021 review summarized by the U.S. National Institutes of Health identified seven stress-and-anxiety trials involving 491 adults. Participants received ashwagandha or placebo for six to eight weeks, and the preparations and daily doses varied widely. Overall results favored ashwagandha on several subjective stress or anxiety measures and sometimes on cortisol, but the trials were generally small, brief, and heterogeneous. Later randomized trials and meta-analyses add supportive findings without resolving product differences or establishing equivalence to prescription treatment.

Stress and Anxiety Symptoms

Some standardized ashwagandha extracts have reduced perceived stress and certain anxiety scores in selected adults during short-term trials. Much of this evidence comes from otherwise healthy people with self-reported stress rather than from large, independently replicated trials in panic disorder, social anxiety disorder, post-traumatic stress disorder, or severe generalized anxiety disorder. Improvement on a rating scale is clinically relevant, but it is not the same as demonstrated remission of a diagnosed disorder.

Cortisol and Stress Biology

Several placebo-controlled trials reported lower serum or morning cortisol after ashwagandha use. Cortisol is a physiological marker influenced by time of day, sleep, illness, exercise, and many other factors; lowering it does not by itself establish recovery from an anxiety disorder. Cortisol reduction should not be treated as a unique pharmacological advantage over every prescription anxiolytic or used alone to select treatment.

Sleep

A 2021 systematic review and meta-analysis found a small overall improvement in sleep with ashwagandha compared with placebo, with larger effects in participants who had insomnia, in studies lasting at least eight weeks, and at daily doses of 600 mg or more. These findings do not make ashwagandha a rescue sedative. Persistent insomnia warrants assessment for psychiatric, respiratory, endocrine, medication-related, substance-related, and other medical causes.

Onset and Clinical Role

Ashwagandha outcomes in the cited trials were assessed after repeated daily use over approximately six to twelve weeks, not minutes or hours. It is therefore unsuitable as an acute treatment for a panic attack, severe agitation, dangerous withdrawal, or another psychiatric crisis. Its most plausible role is as a professionally supervised complementary option for some adults with stress-related symptoms, not as an emergency medicine or an automatic replacement for psychotherapy or prescribed treatment.

Where Prescription Treatment Remains Essential

Clinical severity and diagnosis determine treatment. Guideline-based care may include cognitive behavioral therapy, an SSRI or another appropriate medicine, careful follow-up, and short-term crisis measures when necessary. Ashwagandha is not an established sole treatment for severe or disabling anxiety, recurrent panic attacks, obsessive-compulsive disorder, post-traumatic stress disorder, major depression with anxiety, mania, psychosis, substance withdrawal, or perinatal psychiatric emergencies.

  • Acute panic or crisis: A botanical supplement does not provide predictable rescue treatment. New chest pain, fainting, severe breathlessness, confusion, or neurological symptoms also require medical evaluation rather than being assumed to be anxiety.
  • Marked functional impairment: Inability to work, sleep, eat, leave home, or care for oneself calls for prompt professional assessment and an individualized treatment plan.
  • Self-harm or suicide risk: Suicidal thoughts, intent, planning, or severe hopelessness require urgent local emergency or crisis support.
  • Benzodiazepine use: Physical dependence can develop even when a benzodiazepine is taken as prescribed. Abrupt discontinuation or rapid dose reduction can produce serious withdrawal, including seizures; tapering must be directed by the prescriber.

Ayurvedic Context and Product Identity

The Ayurvedic Pharmacopoeia of India identifies Ashvagandha as the dried mature root of Withania somnifera. A Ministry of AYUSH advisory also distinguishes this root identity from leaf-containing products marketed in the name of Ayurveda. Modern clinical extracts may differ from classical root powder in extraction ratio, excipients, plant part, and withanolide specification, so their trial doses should not be converted directly into doses for churna, avaleha, ghrita, or another Ayurvedic preparation.

Ayurvedic treatment is individualized rather than built from a universal fixed “anxiety stack.” A qualified Ayurvedic practitioner may consider constitution, strength, digestion, sleep, diet, concurrent illness, and current medicines before selecting the drug, form, dose, timing, adjuvant, and duration. Fixed combinations of Ashwagandha, Brahmi, Shankhpushpi, Jatamansi, or Tagara should not be presented as a classically mandated protocol, and modern standardized-extract doses should not be attributed to classical texts.

Using Ashwagandha Alongside Medication

Combining a supplement with treatment is not automatically safer than using either alone. Ashwagandha can cause drowsiness and may interact with sedatives, anticonvulsants, thyroid hormone, immunosuppressants, and medicines for diabetes or high blood pressure. A person taking lorazepam, clonazepam, diazepam, a sleep medicine, or another central nervous system depressant should obtain prescriber approval before adding it because sedation and impaired alertness may increase.

  • Thyroid disease: Ashwagandha may affect thyroid function and has been associated with reports of thyrotoxicosis. People with thyroid disorders or those taking thyroid hormone need clinician guidance and appropriate monitoring.
  • Autoimmune disease or immunosuppression: Use is not recommended without specialist approval because of possible effects on immune activity and potential interaction with immunosuppressive medicines.
  • Surgery: Stop-and-start decisions should be made with the surgical team; NCCIH advises against use around surgery.
  • Driving and machinery: Drowsiness can occur. Avoid driving or hazardous work until individual effects and medicine interactions are clear.

Dose, Duration, and Product Differences

Trial doses describe what investigators tested; they are not a personal prescription. In the seven trials summarized by NIH, extract doses ranged from 240 to 1,250 mg daily, while one study used a much larger amount of whole-root granules. Commonly cited trials used 240 mg once daily, 250 or 600 mg daily, or 300 mg twice daily for six to ten weeks. The varied preparations prevent a single evidence-based dose from being transferred to every commercial product.

Check whether the label specifies root, leaf, or root-and-leaf extract; the extraction ratio; the amount per serving; the withanolide specification; and any additional active ingredients. A higher withanolide percentage is not automatically more appropriate, and branded extracts with different compositions should not be treated as interchangeable. Bring the exact label or a photograph of it to the prescribing clinician and qualified Ayurvedic practitioner.

Safety and Disclaimer

This article is for education and does not constitute medical advice. Short-term use for up to about three months appears generally tolerated in trials, but long-term safety is not established. Reported adverse effects include drowsiness, stomach upset, loose stools, nausea, vomiting, and rare clinically apparent liver injury. Avoid ashwagandha during pregnancy and breastfeeding, and obtain medical advice before use with thyroid or autoimmune disorders, liver disease, upcoming surgery, or any regular medication.

Stop the product and seek medical care for jaundice, dark urine, severe itching, persistent vomiting, unusual fatigue, or upper abdominal pain. Do not discontinue, reduce, or substitute a prescription anxiolytic on the basis of supplement response alone. A validated symptom scale or sleep diary can help document change, but it should supplement—not replace—clinical review. Decisions about continuing either ashwagandha or a prescription medicine should be made with a qualified Ayurvedic practitioner and the healthcare professional managing the anxiety disorder.

References

  1. NIH Office of Dietary Supplements
  2. NCCIH
  3. An alternative treatment for anxiety: a systematic review of human trial results reported for the Ayurvedic herb ashwagandha (Withania somnifera) (2014), PubMed
  4. A double-blind, placebo-controlled evaluation of the anxiolytic efficacy ff an ethanolic extract of withania somnifera (2000), PubMed
  5. Journals (journals.plos.org)
  6. A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and anxiety in adults (2012), PubMed
  7. A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and anxiety in adults (2012), PubMed Central
  8. An investigation into the stress-relieving and pharmacological actions of an ashwagandha (Withania somnifera) extract: A randomized, double-blind, placebo-controlled study (2019), PubMed
  9. An investigation into the stress-relieving and pharmacological actions of an ashwagandha (Withania somnifera) extract: A randomized, double-blind, placebo-controlled study (2019), PubMed Central
  10. Adaptogenic and Anxiolytic Effects of Ashwagandha Root Extract in Healthy Adults: A Double-blind, Randomized, Placebo-controlled Clinical Study (2019), PubMed
  11. Adaptogenic and Anxiolytic Effects of Ashwagandha Root Extract in Healthy Adults: A Double-blind, Randomized, Placebo-controlled Clinical Study (2019), PubMed Central
  12. Efficacy and Safety of Ashwagandha (Withania somnifera) Root Extract in Insomnia and Anxiety: A Double-blind, Randomized, Placebo-controlled Study (2019), PubMed
  13. Efficacy and Safety of Ashwagandha (Withania somnifera) Root Extract in Insomnia and Anxiety: A Double-blind, Randomized, Placebo-controlled Study (2019), PubMed Central
  14. Journals (journals.plos.org)
  15. Examining the effect of Withania somnifera supplementation on muscle strength and recovery: a randomized controlled trial (2015), PubMed
  16. Nice (nice.org.uk)
  17. Cks (cks.nice.org.uk)
  18. FDA
  19. Ministry of AYUSH
  20. Ayush (ayush.delhi.gov.in)
  21. NCBI
Tags: anxiety Anxiolytics Ashwagandha clinical trials Pharmaceutical Comparison research